US › Healthcare

Orchestra BioMed Holdings Inc. (OBIO)

US · Healthcare · Biotechnology

$5.68+1.07%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

$88,000

Revenue YoY

-89.5%

Net profit

$-23.8M

EPS

$-0.38

EPS estimate

$-0.35

Net margin

-26,994.3%

EPS came in at -0.38 against a street estimate of -0.35 — a miss of 8.6%.

Key statistics

Market cap

$337.8M

Forward P/E

0.0

P/B

17.26

Book value

$0.32

EPS (TTM)

$-0.86

52-week high

$6.50

52-week low

$3.46

50-day MA

$5.72

200-day MA

$4.56

Beta

0.55

Analyst view

Analysts rate Orchestra BioMed Holdings Inc. a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $12.43.

Shareholding

Insiders

24.42%

Institutions

47.82%

Largest institutional holders

Fund	Stake
RTW INVESTMENTS, LLC	15.90%
Perceptive Advisors LLC	8.38%
BlackRock Inc	4.18%
Vanguard Capital Management, LLC	3.37%
Geode Capital Management, LLC	1.68%
Alyeska Investment Group, L.P.	1.66%
Propel Bio Management LLC	1.49%
UBS Asset Mgmt Americas Inc	1.07%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Orchestra BioMed Holdings Inc. — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.